Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

ADC Therapeutics (ADCT) EBIT (2019 - 2026)

ADC Therapeutics has reported EBIT over the past 8 years, most recently at -$25.2 million for Q1 2026.

  • Quarterly results put EBIT at -$25.2 million for Q1 2026, up 11.31% from a year ago — trailing twelve months through Mar 2026 was -$128.8 million (down 1.69% YoY), and the annual figure for FY2022 was -$123627.0, up 99.94%.
  • EBIT reached -$25.2 million in Q1 2026 per ADCT's latest filing, up from -$31.0 million in the prior quarter.
  • Across five years, EBIT topped out at $3.0 billion in Q2 2023 and bottomed at -$10.7 billion in Q4 2022.
  • Median EBIT over the past 5 years was -$34.6 million (2024), compared with a mean of -$581.8 million.
  • Peak annual rise in EBIT hit 4452.34% in 2023, while the deepest fall reached 1060.85% in 2023.
  • Over 5 years, EBIT stood at -$10.7 billion in 2022, then skyrocketed by 99.66% to -$36.1 million in 2023, then grew by 1.62% to -$35.6 million in 2024, then grew by 12.92% to -$31.0 million in 2025, then grew by 18.48% to -$25.2 million in 2026.
  • Business Quant data shows EBIT for ADCT at -$25.2 million in Q1 2026, -$31.0 million in Q3 2025, and -$44.1 million in Q2 2025.